Displaying 761 - 780 of 1549
FTC Staff: Massachusetts Should Consider Removing Physician Supervision Requirements for Nurse Practitioners and Nurse Anesthetists
FTC Requires Community Health Systems, Inc. to Divest Two Hospitals as a Condition of Acquiring Rival Hospital Operator
Statement of Commissioner Maureen K. Ohlhausen Dissenting in Part and Concurring in Part
Accretive Health Settles FTC Charges That It Failed to Adequately Protect Consumers’ Personal Information
FTC Approves Final Order Settling Charges That Mylan, Inc.’s Acquisition of Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. Was Anticompetitive
Mylan Inc., Agila Specialties Global Pte.Limited, Agila Specialties Private Limited, and Strides Arcolab Limited, In the Matter of
Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila are two of only a limited number of current or likely future competitors. The number of suppliers in generic pharmaceutical markets matters because prices generally decrease as the number of competing generic suppliers increases. In addition, the injectable generic products of concern are highly susceptible to supply disruptions caused by the inherent difficulties of producing sterile liquid drugs.
FTC Approves Final Order Settling Charges that Actavis, Inc.’s Acquisition of Warner Chilcott plc Would Be Anticompetitive in Four Current and Future Drug Markets
Actavis, Inc. and Warner Chilcott PLC, In the Matter of
Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).
FTC Announces Agenda for Workshop Examining Competition Issues Surrounding Biologic and Follow-on Biologic Medicines: Biosimilars and Interchangeables
FTC Staff Submits Comment to the Commission on Dental Accreditation Regarding its Proposed Standards for Dental Therapy Education Programs
FTC to Host Spring Seminars on Emerging Consumer Privacy Issues
Prepared Statement of the Â鶹´«Ã½ Trade Commission On "Oversight of the Â鶹´«Ã½ of the Antitrust Laws"
FTC Chairwoman Ramirez Testifies Before House Judiciary Subcommittee on Agency’s Â鶹´«Ã½ of U.S. Antitrust Laws to Promote Competition and Protect Consumers
FTC to Host Workshop on the Competitive Impacts of State Regulations and Naming Conventions Concerning Follow-on Biologics
FTC Finalizes Amendments to the Premerger Notification Rules Related to the Transfer of Exclusive Patent Rights in the Pharmaceutical Industry
Economics at the FTC: Physician Acquisitions, Standard Essential Patents, and Accuracy of Credit Reporting
FTC Charges HCG Marketer with Deceptive Advertising
Displaying 761 - 780 of 1549